Claims for Patent: 5,128,321

Summary for Patent: 5,128,321

Title:	PDGF analogs and methods of use
Abstract:	Proteins having substantially the same biological activity as PDGF are provided. In one aspect, a protein homodimer having two polypeptide chains is disclosed, each of the chains being a mosaic of amino acid sequences substantially identical to portions of the A- and B-chains of PDGF, the protein being chemotactic or mitogenic for fibroblasts. Therapeutic compositions comprising such proteins in combination with a physiologically acceptable carrier or diluent are also provided. Such therapeutic compositions may be used within methods for enhancing the wound-healing process in warm-blooded animals.
Inventor(s):	Murray; Mark J. (Seattle, WA), Kelly; James D. (Seattle, WA)
Assignee:	ZymoGenetics, Inc. (Seattle, WA)
Application Number:	07/230,190
Patent Claims:	1. A substantially pure protein homodimer having substantially identical to the A-chain of PDGF, as shown in FIGS. 3H or 3I. 2. A protein homodimer having two polypeptide chains, each of said chains being a mosaic of amino acid sequences substantially identical to portions of the A- or B-chains of PDGF, said protein being chemotactic or mitogenic for fibroblasts. 3. A protein of claim 2 wherein each of said chains substantially identical to the A-chain of PDGF, as shown in FIGS. 3A-3G. 4. A therapeutic composition comprising a protein homodimer having two polypeptide chains, each of said chains being substantially identical to the A-chain of PDGF, as shown in FIGS. 3H or 3I, and a physiologically acceptable carrier. 5. A therapeutic composition comprising a protein homodimer having two polypeptide chains, each of said chains being a mosaic of amino acid sequences substantially identical to portions of the A- or B-chains of PDGF, said protein being chemotactic or mitogenic for fibroblasts, and a physiologically acceptable carrier. 6. The therapeutic composition of claim 5 wherein each of said chains is substantially identical to the A-chain of PDGF, as shown in FIGS. 3A-3G. 7. The therapeutic composition of claim 4, 5, or 6 wherein said carrier is selected from the group consisting of albumin, sterile water, polyethylene glycol and saline. 8. The therapeutic composition of claim 4, 5 or 6, including an adjuvant. 9. The therapeutic composition of claim 8 wherein said adjuvant is selected from the group consisting of collagen, hyaluronic acid, fibronectin, factor XIII and an antibiotic. 10. The therapeutic composition of claim 4, 5 or 6 wherein said protein is present in a concentration of from about 10 to 100 .mu.g/ml of total volume. 11. The therapeutic composition of claim 4, 5 or 8 wherein said composition includes a stabilizer. 12. The therapeutic composition of claim 4, 5 or 6, including an effective amount of basic fibroblast growth factor. 13. The therapeutic composition of claim 12 wherein the protein homodimer and the fibroblast growth factor are present in a ratio of from approximately 1 to 0.4 to 10 to 0.4, respectively. 14. A method for enhancing the wound-healing process in a warm-blooded animal, comprising administering to the animal a therapeutically effective amount of a composition comprising a protein homodimer having two polypeptide chains, each of said chains being substantially identical to the A-chain of PDGF, as shown in FIGS. 3H or 3I, and a physiologically acceptable carrier. 15. A method for enhancing the wound-healing process in warm-blooded animals, comprising administering to the animal a therapeutically effective amount of a composition comprising a protein homodimer having two polypeptide chains, each of said chains being a mosaic of amino acid sequences substantially identical to portions of the A- or B-chains of PDGF, said protein being chemotactic or mitogenic for fibroblasts, and a physiologically acceptable carrier. 16. The method of claim 15 wherein each of said chains is substantially identical to the A-chain of PDGF, as shown in FIGS. 3A-3G. 17. The method of claim 14, 15 or 16 wherein said carrier is selected from the group consisting of albumin, sterile water, polyethylene glycol and saline. 18. The method of claim 14, 15 or 16 wherein said composition includes an adjuvant. 19. The method of claim 14, 15 or 16 wherein said composition is administered topically. 20. The method of claim 14, 15 or 16 wherein said protein homodimer is administered in a dose of from about 0.5 to 10 .mu.g per cm.sup.2 of wound area. 21. The method of claim 14, 15 or 16 wherein said composition includes an effective amount of basic fibroblast growth factor. 22. The method of claim 21 wherein the protein homodimer and the fibroblast growth factor are present in a ratio of from approximately 1 to 0.4, to 10 to 0.4 respectively. 23. The method of claim 14, 15 or 16 wherein said warm-blooded animal is a diabetic animal. 24. A method for enhancing the wound-healing process in warm-blooded animals, comprising administering to the animal a therapeutically effective amount of a composition comprising a protein homodimer having two polypeptide chains, each of said chains being substantially identical to either the A-chain or B-chain of PDGF, said protein being chemotactic or mitogenic for fibroblasts, and a physiologically acceptable carrier.

Details for Patent 5,128,321

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2004-10-12